Alzheimer's Disease: Current Status and Future Prospects
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 7921
Special Issue Editors
Interests: neurodegeneration; biomarker; tau; amyloid-beta
Special Issue Information
Dear Colleagues,
This special Edition “Alzheimer’s disease: Current State and Future Prospects will mainly focus on the Alzheimer’s disease (AD) and its potential disease-modifying diagnostics and therapeutics that are currently being studied and advances that can be proved beneficial for patients with AD. AD is one of the major neurodegenerative disease-causing dementias and causes significant burden both physically and mentally in elderly population and their caregivers. AD is characterized by either extra cellular accumulation of amyloid beta in the form of amyloid plaques or intracellular accumulation of tau in the form of neurofibrillary tangles. Despite of several efforts to find effective ways to prevent or slowing down of disease progression, AD remains as a disease without cure. Hence the current edition mainly focuses on the diagnostic biomarkers such as tau, amyloid beta or other circulating proteins that helps in the earlier diagnosis and thereby preventing its progression.
We cordially invite authors in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.
Dr. Sireesha Manne
Dr. Naveen Kondru
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- tau
- biomarker
- diagnosis
- APOE
- amyloid beta
- slow progression
- fast progression